Pharmacological & biochemical characterization of antiparkinson drugs in reserpinized mice.
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001259:Ataxia / Q000139:chemically induced / Q000188:drug therapy*; D001763:Blepharoptosis / Q000139:chemically induced / Q000188:drug therapy*; D002389:Catatonia / Q000139:chemically induced / Q000188:drug therapy*; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D051379:Mice; D010095:Oxotremorine / Q000009:adverse effects; D012110:Reserpine / Q000009:adverse effects; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy*
D000978:Antiparkinson Agents; D010095:Oxotremorine; D012110:Reserpine